Sign In  |  Register  |  About Menlo Park  |  Contact Us

Menlo Park, CA
September 01, 2020 1:28pm
7-Day Forecast | Traffic

  • Search Hotels in Menlo Park

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cymabay Therapeutics (NQ: CBAY )

8.540 +0.190 (+2.28%)
Streaming Delayed Price Updated: 3:15 PM EST, Feb 7, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 736,130
Open 8.310
Bid (Size) 8.530 (9)
Ask (Size) 8.540 (3)
Prev. Close 8.350
Today's Range 8.295 - 8.590
52wk Range 1.670 - 8.750
Shares Outstanding 84,677,939
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Why Baudax Bio Shares Are Trading Higher By 60%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Baudax Bio, Inc. (NASDAQ: BXRX) shares surged 59.7% to $5.03 after the company announced the outcome of its first interim analysis in a Phase II trial of BX1000 for neuromuscular blockade in... 
Via Benzinga
Why CymaBay Therapeutics Shares Are Rising
CymaBay Therapeutics Inc (NASDAQ: CBAY) shares are trading higher by 9.30% to $7.22 Tuesday morning. The company priced a public offering of common stock and pre-funded warrants at $7 per share and... 
Via Benzinga

Performance

YTD
+43.29%
+43.29%
1 Month
+44.26%
+44.26%
3 Month
+155.69%
+155.69%
6 Month
+111.91%
+111.91%
1 Year
+176.38%
+176.38%

More News

Read More
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
5 Most Expensive Health Care Stocks You Should Worry About
Via Benzinga
CymaBay's New Seladelpar Two-Year Data Shows Improved Transplant-Free Survival
Via Benzinga
CymaBay Therapeutics: Q1 Earnings Insights
Via Benzinga
CymaBay Therapeutics: Q2 Earnings Insights
Via Benzinga
Earnings Outlook For CymaBay Therapeutics
Via Benzinga
Recap Of Monday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
38 Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
76 Biggest Movers From Yesterday: Ocean Bio-Chem, Athira Pharma And More
Via Benzinga
The Week Ahead In Biotech (May 22-28): Verrica, Bristol-Myers Squibb FDA Decisions, Medtronic Earnings, Conference Presentations & More
Via Benzinga
79 Biggest Movers From Yesterday
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
The Daily Biotech Pulse: Bristol Myers, BridgeBio Ink Oncology Pact, FDA Nod For Lava Therapeutics Blood Cancer Study And More
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
The Daily Biotech Pulse: Moderna Files For 2nd COVID Booster Shot Authorization, Lexicon Secures Debt Funding, Amneal Gets Sub-License to Manufacture Generic COVID Pill
Via Benzinga
CymaBay Therapeutics: Q4 Earnings Insights
Via Benzinga
The Daily Biotech Pulse: AbbVie's Rinvoq Gets Label Expansion, AstraZeneca COVID Antibody Cocktail Authorized By UK Regulator, Stealth Touts Positive Data
Via Benzinga
A Preview Of CymaBay Therapeutics's Earnings
Via Benzinga
Mid-Afternoon Market Update: Crude Oil Drops 2%; Limelight Networks Shares Spike Higher
Via Benzinga
Earnings Scheduled For March 17, 2022
Via Benzinga
Mid-Day Market Update: Dow Falls 100 Points; Netflix Shares Plummet
Via Benzinga
The Week Ahead In Biotech (March 13-19): Bristol-Myers Squibb's Melanoma Drug Decision, Multiple Conference Presentations And Earnings Dominate Proceedings
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MenloPark.com & California Media Partners, LLC. All rights reserved.